Relationship between PSA and Serum Zinc in BPH-Afflicted Iraqi Men

Abstract

Background: Benign prostatic hyperplasia (BPH) is a common benign tumor of the prostate that becomes more common as men age. The enlarged prostate may compress the urinary tube (urethra), which runs through the middle of the prostate, preventing urine from flowing from the bladder to the outside. Complete obstruction can develop if BPH is severe enough. BPH usually appears after the age of 40 and progresses slowly. Aim of the Study: Studying the connections between serum zinc and PSA in Iraqi BPH patients is the aim of this investigation. Patients and Methods: The case-control study lasted three months, from mid-November to the end of February, at Al-Kindi Teaching Hospital and Ghazy Al-Hariri Hospital in Baghdad Governorate, Iraq. It entailed gathering 90 blood samples, which were separated into two groups. The first group (A) consisted of 60 patients with benign prostatic hyperplasia ranging in age from 45 to 80 years, while the second group (B) consisted of 30 apparently be healthy males aged 45 to 80 years. All participants in this study provided diagnose permission. Patients diagnosed with benign prostate hyperplasia had an international prostate symptom score of 18 or higher; the patient's prostate volumes (PV) were equal to or more than 25 milliliters. Radiologists with competence in the department used transabdominal ultrasound equipment manufactured in Germany by Siemens to figure out how big the prostate gland is. Both groups had their serum zinc and PSA levels measured by ELISA (Enzyme-Linked Immunosorbent Assay) assays The calculation of BMI was be calculated with the help of given standard formula. BMI = [(Weight in Kilograms / (Height in Meters x Height in Meters)]. Results: The study that the mean prostate size was elevated significantly in the BPH group (54.0 ± 8.4 cc ) as compared with the control group (19.66 ± 2.88 cc (P:0.01). There is a significant increase in the PSA concentration of benign prostatic hyperplasia patients, (3.14 ± 0.95 ng/ml), as compare with control subjects, (0.84 ± 0.10 ng/ml) (P:0.01). There is significant reduction in the serum zinc concentration of benign prostatic hyperplasia patients, (70.4 ± 9.63 ng/ml), as compare with control subjects, (99.3 ± 10.5; p≤0.01). The higher percentage of benign prostatic hyperplasia in patients above 66 years, and the lowest is in age group 45-55 years. Conclusion: Benign prostatic hyperplasia patients of all ages had considerably higher serum PSA than age-matched healthy controls. Benign prostatic hyperplasia patients of all ages had considerably lower serum zinc than age-matched healthy controls. Prostate size and PSA are greater in benign prostatic hyperplasia patients of all BMIs. Benign prostatic hyperplasia patients had significantly lower serum zinc than healthy controls of the same BMI.